Evolut platform’s transcatheter aortic valve implantation in BIVOLUTX registry for bicuspid aortic valve stenosis

This study evaluated the use of self-expanding prostheses in patients with bicuspid aortic valve (BAV) and explored the impact of different computed tomography sizing algorithms in a prospective registry. A total of 149 bicuspid patients were treated in 14 countries, and the study found that the intended valve performance at 30 days was observed in 95.3% of patients. Secondary endpoints, including 30-day and 1-year mortality, severe patient-prosthesis mismatch, and the ellipticity index, were measured and found to be similar between the two sizing strategies evaluated. Overall, the study suggests that transcatheter aortic valve implantation (TAVI) is a safe and effective treatment option for BAV patients.

Upcoming Conference

ECE 2023

MAY 13-16 2023, Istanbul, Turkey
25th European Congress of Endocrinology

Scroll to Top